Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Cyclo Therapeutics Inc (CYTH)

7.84   -0.4 (-4.85%) 03-05 08:43
Open: 8.2 Pre. Close: 8.24
High: 8.49 Low: 7.6
Volume: 276,564 Market Cap: 36M

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 8.508 - 8.559 8.559 - 8.597
Low: 7.488 - 7.55 7.55 - 7.596
Close: 7.757 - 7.85 7.85 - 7.92

Technical analysis

as of: 2021-03-05 8:09:14 AM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 15.45     One year: 20.73
Support: Support1: 5.92    Support2: 4.93
Resistance: Resistance1: 13.23    Resistance2: 17.75
Pivot: 9.00
Moving Average: MA(5): 8.28     MA(20): 9.72
MA(100): 8.40     MA(250): 12.79
MACD: MACD(12,26): 0.10     Signal(9): 0.42
Stochastic oscillator: %K(14,3): 11.84     %D(3): 11.38
RSI: RSI(14): 46.46
52-week: High: 30.00  Low: 3.00  Change(%): -44.0
Average Vol(K): 3-Month: 160972  10-Days: 24094

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
CYTH has closed above bottom band by 20.1%. Bollinger Bands are 29.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Thu, 04 Mar 2021
Cyclo Therapeutics (CYTH) Reports Complete Patient Visit in Phase 1/2 Trial Evaluating Trappsol Cyclo for Treatment of Niemann-Pick Disease Type C -

Thu, 04 Mar 2021
Cyclo Therapeutics Announces Last Patient Last Visit in Phase 1/2 Trial Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C - Business Wire

Tue, 02 Mar 2021
Cyclo Therapeutics (CYTH) Receives a Buy from Maxim Group - Smarter Analyst

Mon, 01 Mar 2021
Cyclo Therapeutics Appoints Gerald F. Cox, MD, PhD as Acting Chief Medical Officer - Business Wire

Mon, 22 Feb 2021
Cyclo Therapeutics Unveils New Corporate Identity and Reaffirms Commitment to Improving Quality of Life and Providing Hope for Patients and Families - Valdosta Daily Times

Tue, 16 Feb 2021
Cyclo Therapeutics: A Potential Gem In The Fight Against Alzheimer's Disease - Seeking Alpha

Financial Analysis

Growth NA
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability NA
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency NA
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency NA
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Neutral Discounted cash flow: Neutral
Return on Assets: Neutral Price to Earnings: Neutral
Return on Equity: Neutral Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Shares Out. (M) 5
Shares Float (M) 1
% Held by Insiders 10.24
% Held by Institutions 0.06
Shares Short (K) 126
Shares Short P. Month (K) 5

Stock Financials

EPS Est This Year
EPS Est Next Year
Book Value (p.s.)
Profit Margin
Operating Margin -905.22
Return on Assets (ttm) -111.5
Return on Equity (ttm) -601.4
Qtrly Rev. Growth -22.2
Gross Profit (p.s.) 0.168
Sales Per Share 0.216
EBITDA (p.s.) -1.950
Qtrly Earnings Growth
Operating Cash Flow (M) -8
Levered Free Cash Flow (M) -4

Stock Valuations

PE Ratio
PEG Ratio
Price to Book value
Price to Sales 36.37
Price to Cash Flow -4.65

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.